Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BARCONA: A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)

Next Previous
X
Search
Trial Profile

BARCONA: A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Acute kidney injury; COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BARCONA

    • Most Recent Events

    • 22 Feb 2021 Phase of the trial is changed from 2/3 to 2, also removing the phase 3 primary end-point and re-labelling the phase 2 cohort as Experimental: Bardoxolone Methyl and phase 3 cohort as Placebo arm.
    • 22 Feb 2021 Status changed from recruiting to completed.
    • 11 Feb 2021 Planned End Date changed from 28 Feb 2021 to 1 Sep 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top